Objective: Intercellular adhesion molecule (ICAM)-1 is an immunoglobulin-like cell adhesion molecule expressed by several cell types, including proliferating vascular smooth muscle cells (VSMC). Cross-linking ICAM-1 on the surface of different cell types has previously been shown to cause an increase in cellular activation within the cytoplasm. Here, our objective was to examine events following ligation of ICAM-1 on the surface of human VSMC. Methods: VSMC were isolated by explant from human pulmonary arteries or aortic tissue from cardiac transplant donors. ICAM-1 was ligated with monoclonal antibodies, followed by cross-linking with a secondary antibody. Activation of signalling pathways, proliferation and expression of a second adhesion molecule, vascular cell adhesion molecule (VCAM)-1 were investigated. Results: ICAM-1 cross-linking caused an increase in activation of extracellular regulated kinase (Erk)-1 / -2 and Jun N-terminal kinase (JNK)-1 / -2. mRNA and protein for VCAM-1 was observed after ICAM-1 cross-linking, and this was abrogated by addition of an upstream inhibitor of Erk-1 / -2, PD98059. No increase in cell proliferation was observed. Conclusions: Ligation of ICAM-1 on the surface of vascular smooth muscle cells in vitro, leads to the expression of adhesion molecules associated with monocyte infiltration, but does not contribute to smooth muscle cell proliferation. In vivo, this might lead to prolongation of the inflammatory response within diseased blood vessels, by arresting monocytes within atherosclerotic plaques.
Introduction
cells (VSMC) together with variable numbers of macrophages and T lymphocytes, the presence of lipids, parAtherosclerosis is the principal cause of death in Westticularly in the form of cholesteryl esters, and the formaern civilisation. The atherosclerotic lesion is characterised tion of large amounts of connective tissue matrix [1] [2] [3] . by the accumulation of intimal vascular smooth muscle
The presence of VSMC is also a feature of transplant atherosclerosis and restenosis injury [4] . VSMC, which migrate from the media of the artery wall to the intima molecules involved in leukocyte trafficking across endoplastic these were trypsinised and maintained as monothelial cells and possibly in VSMC migration [10] [11] [12] [13] [14] [15] [16] [17] .
layers in full VSMC medium, as above. Confluent mono-ICAM-1 (CD54) is a 90-kDa member of the Ig superlayers of single isolates at between passages 3-10 were family and is also found on the surface of several other cell used for all experiments. Cells were identified as VSMC by types, including leukocytes and endothelial cells. It has positive staining for smooth muscle a-actin, a recognised been shown to have a number of different ligands includmarker of smooth muscle cells [27] (see below). Results ing LFA-1, Mac-1, fibrinogen, rhinoviruses and plasare shown for individual isolates derived from aorta or modium falciparum [18] . The role of ICAM-1 as an pulmonary artery. We have seen no differences between adhesive molecule has been described in detail elsewhere VSMC from these two sources. Dako, Cambridge, UK) was used at 1:100 for crossexpression of VCAM-1, a process which is independent of linking. Protein G purified fractions of CRL1724 (ATCC), NF-kB activity [23] . Tyrosine phosphorylation of the cell an IgG1 isotype MAb that recognises v-myb and chicken cycle protein, cdc2 kinase, occurs in T cells [24] , whilst c-myb, were used at 20 mg / ml as an irrelevant antibody peripheral blood mononuclear cells [25] ) and synovial control. Protein G purified fractions of anti-VCAM-1 clone cells [26] are also activated by ICAM-1 cross-linking.
1.4C3 (a kind gift of Professor D. Haskard; National Heart ICAM-1 signalling in VSMC has not been investigated.
and Lung Institute, London, UK; [28] were used at 250 Signal transduction via ICAM-1 could have implications ng / ml for blotting and 2.5 mg / ml for immunoprecipitation. for the pathogenesis of vascular diseases where VSMC Anti-VCAM-1 mAb BBIG-VI (R1D Systems, Abingdon, migrate to the vessel intima. For example, interaction UK) was used at 10 mg / ml for blotting and immunobetween ICAM-1 on VSMC and LFA-1 on infiltrating precipitation. Anti-active Erk-1 (Promega, Southampton leukocytes could help maintain the chronicity of the UK) was used at 1:5000 for blotting. Anti-Erk-1 (Translesions. duction Laboratories; purchased from Affiniti Biosystems, Here, we have cross-linked ICAM-1 on the surface of Exeter UK), anti-active JNK-1 and anti-JNK-1 (Santa human vascular smooth muscle cells in order to determine Cruz, purchased from Insight Biotechnology, London, UK) the down stream signalling events and possible biological were used at 1:400 for blotting. Anti-IkBa (Santa Cruz) end-points of such signalling.
was used at 1:200 for blotting. Goat anti-murine and goat anti-rabbit horseradish peroxidase-conjugated secondary antibodies were purchased from Jackson (Stratech, Luton, 2. Methods UK) and were used at 1:5000 as secondary antibodies. Protein-G purified fractions of anti-human MHC class I 2.1. Cell culture (clone W6 / 32 ATCC) were used at 10 mg / ml for indirect immunofluorescence staining. Anti-smooth muscle a-actin VSMC were isolated from pulmonary arteries or aortic (Clone 1A4; Sigma) was used at 1:100 for indirect tissue from donors at heart transplant, by explant. 378C in a 5% CO atmosphere. VSMC were allowed to were analysed using a Coulter EPICS flow cytometer. 2 4 migrate out onto the plastic over a period of 2-8 weeks.
Alternatively, 5310 HVSMC were plated onto sterile Once there were large colonies of VSMC adhered to the coverslips and allowed to adhere for 48 h. Coverslips were washed in PBS and then fixed for 5 min in ice-cold 2.6. Immunoprecipitation acetone. They were stained for the presence of smooth muscle a-actin, ICAM-1 or MHC class I, followed by goat Cells were stimulated and lysed as described above for anti-mouse Ig F(Ab)2-ALEXA 594 nm. Positively stained Western blotting in Section 2.4. Each cell lysate (100 mg) cells were visualised with a fluorescent microscope (Axwas incubated with primary antibody and 20 ml protein-G iophot, Zeiss, Hertfordshire, UK). VSMC selected for sepharose slurry (Sigma) for 18 h at 48C with mixing. experiments expressed both smooth muscle a-actin and Beads were pelleted and washed four times in RIPA buffer, ICAM-1.
before being resuspended in 100 ml SDS gel loading buffer without reducing agents. The beads were boiled for 5 min and pelleted again. Supernatants were electrophoresed on 2.4. Western blotting and immunodetection 10% polyacrylamide gels, blotted and probed as described above. VSMC were plated onto 6-cm dishes. Once confluent, Cells were pretreated with proteasome inhibitor I (PSI; the cells were washed in serum-free DMEM and then Calbiochem, Nottingham, UK) at a final concentration of incubated in DMEM with 1% FCS for 18 h in order to 10 mM in order to inhibit NF-kB activation [29] , or with minimise activation by serum. Cells were incubated in 30 mM PD98059 (Calbiochem) to inhibit Erk activity DMEM; 1% FCS for the duration of experiments. Anti- [30, 31] . ICAM-1 antibody was added and the cells were incubated for 30 min at 378C. Cells were washed once with serum 2.7. RT-PCR free DMEM and incubated with RAM at a dilution of 1:100. As a positive control, VSMC were incubated with VSMC were plated onto 24-well dishes. Confluent 100 u / ml recombinant human TNF (R1D Systems) monolayers were allowed to quiesce in DMEM with 1% together with 100 u / ml IL-1b (Insight Biotechnology) for FCS for 18 h. Cells were washed in serum-free DMEM 15 min at 378C. Monolayers were harvested as described and replaced with 0.5 ml DMEM with 1% FCS. Antipreviously [23] . Protein (25 mg) was electrophoresed on ICAM-1 antibody was added with or without RAM and 10% polyacrylamide gels and blotted onto nitrocellulose cells were incubated at 378C for up to 72 h. The medium membrane (Amersham International; Amersham, UK).
was removed from each well and snap frozen on dry ice After blocking in 5% non-fat milk; PBS; 0.01% followed by storage at 2708C for further analysis. Total (marvel PBS-T), membranes were incubated in primary RNA was extracted from the cells using Purescript total antibodies for 1 h with agitation followed by three washes RNA isolation kits (Flowgen, Staffordshire, UK) or TRI in PBS-T. The membranes were incubated with approReagent (Helena Biosciences; Sunderland, UK) according priate secondary antibodies conjugated to horseradish to the manufacturer's instructions. RT-PCR was carried peroxidase and after three washes in PBS-T, incubated in out using a one-step protocol. Briefly, cDNA synthesis and ECL reagents (Amersham) and exposed to autoradiography PCR was carried out using 5 units AMV reverse tranfilm (Amersham).
scriptase (Promega), 7 units TFL polymerase (Promega) and 25 nmol specific oligodeoxynucleotide primer pairs for b-actin or VCAM-1 (MWG Biotech, Germany; for se-2.5. Proliferation assays quences see Ref. [23] ) together with the manufacturers buffer, 200 mmol dNTP and 12.5 nmol MgSO . Two 4 4 VSMC were plated onto 24-well dishes at 2.5310 cells microlitres of each RNA sample was used per RT-PCR per well. Cells were quiesced in DMEM with 1% FCS for reaction. PCR was performed in a Hybaid Omnigene 48 h. They were washed in serum-free DMEM and thermal cycler (Hybaid, Middlesex, UK) with an initial replaced with 0.5 ml DMEM with 1% FCS. They were incubation of 488C for 45 min, followed by 30 cycles of then incubated with anti-ICAM-1 antibody with or without 948C for 1 min, 558C for 1 min, 728C for 1 min, followed RAM, at 378C for up to 72 h. As a positive control, VSMC by a final incubation at 688C for 7 min. VCAM-1 primers were incubated with 100 u / ml recombinant human PDGFwere designed to span intron-exon boundaries. The up-3 BB (R1D systems) for 48 h at 378C.
[ H] TdR was added stream primer bound between bp1424-1442 (exon VII, Ig to all wells for the last 24 h of culture. The medium was domain 6) and the downstream primer bound between removed and 0.5 ml ice cold 10% trichloroacetic acid 1683 and 1664 (exon VIII, Ig domain 7) of human VCAM-(TCA) was added to each well. Cells were incubated for 20 1 cDNA [32] , with an expected product of 260 base pairs min at 48C, washed once with 1 ml distilled water, and [33] ). then lysed in 0.1 M SDS; 0.3 M NaOH at 378C for 1.5 h with agitation. Lysates were removed from the wells and placed into scintillation vials containing 3 ml scintillation 2.8. Statistics fluid (Packard, Pangbourne, UK). Vials were counted for 1 min on a Beta counter (1600TR, Packard).
Mann-Whitney U nonparametric tests were performed
induced a large increase in activity of JNK-1 / -2 ( Fig. 2B) . Depletion of IkBa after ICAM-1 cross-linking was examined. As shown in Fig. 3 there was no depletion of
Results
IkBa after up to 1 h cross-linking. In contrast, treatment of VSMC with TNF / IL-1b for 15 min lead to a complete 3.1. Expression of ICAM-1 by cultured VSMC depletion of IkBa from the cytosol.
Cultured aortic and pulmonary artery VSMC used in this 3.3. Proliferation of VSMC after ICAM-1 cross-linking study were positive for cell surface expression of ICAM-1 and MHC class I, analysed by flow cytometry (Fig. 1) and Since VSMC have been shown previously to respond to indirect immunofluorescence (not shown). The VSMC used a wide variety of stimuli with increased growth factor also expressed smooth muscle a-actin (data not shown).
expression and increased proliferation, the effect of ICAM-1 cross-linking on these two responses was investigated.
Activation of signalling cascades after ICAM-1
No increase in proliferation after ICAM-1 cross-linking for 3 cross-linking on the surface of VSMC up to 72 h was observed, measured by [ H] TdR incorporation (Fig. 4) . In contrast, incubation of serum starved In agreement with our previous results after ICAM-1 VSMC with recombinant PDGF-BB for 24 h caused a cross-linking on the surface of HUVEC [23] , activation of significant increase in proliferation (P,0.001). No inextracellular regulated kinase (Erk)-1 / -2 was observed crease in mRNA for PDGF B chain, TGFb1 or bFGF was within 5 min of cross-linking VSMC with anti-ICAM-1 observed after ICAM-1 cross-linking (data not shown). antibodies ( Fig. 2A) . This returned to basal levels of activity by 30 min after cross-linking. Ligation of ICAM-1 3.4. Expression of VCAM-1 after ICAM-1 cross-linking for 10 min, without cross-linking also induced Erk-1 / -2 in VSMC activity. There was no effect of incubation of cells for 10 min with CRL1724, an isotype matched control antibody.
To investigate the possibility that ICAM-1 ligation on Incubation of VSMC with TNF / IL-1b for 15 min also the surface of VSMC leads to the induction of other cell induced high levels of Erk-1 / -2 activation, as expected adhesion molecules, RT-PCR was carried out on RNA ( Fig. 2A) . Pre-incubation of VSMC with PD98059, an extracts of ICAM-1 cross-linked cells, for full-length inhibitor of the upstream kinase MAPK / Erk kinase VCAM-1 mRNA, using specific intron-spanning oligo-((MEK); [30, 31] ), abrogated the Erk-1 / -2 activity seen deoxynucleotide primers. Resting VSMC expressed low ( Fig. 2A) . levels of VCAM-1 mRNA, however, after 6 h crossIn contrast to our results with HUVEC [23] , activation linking an increase in VCAM-1 message was observed of Jun N-terminal kinase (JNK)-1 / -2 was observed within (Fig. 5A) . Pre-treatment of VSMC with PD98059 abro-10 min after ICAM-1 cross-linking (Fig. 2B) . This activity gated its expression. returned to basal levels by 1 h cross-linking. Treatment of We examined whether the increase in VCAM-1 mRNA was accompanied by an increase in protein expression after ICAM-1 cross-linking in VSMC. One limitation of mimicking cell-cell interactions by cross-linking with monoclonal antibodies is the difficulty of examining cell surface proteins by flow cytometry or immunocytochemistry, due to unwanted reactions between the antibodies used to stain, with the RAM used to cross-link the cells. Thus, VCAM-1 was immunoprecipitated from whole cell extracts and immunodetection was conducted after resolution by SDS-PAGE, using MAbs directed against the same or different epitopes of VCAM-1. There was slight induction of VCAM-1 protein after treatment of VSMC with anti-ICAM-1 alone or RAM alone, but we observed a large increase in immunoprecipitated VCAM-1 after 12 h Resting VSMC from human aorta were treated with 15 mg/ml anti-ICAM-1 MAb for 30 min at 378C, followed by RAM for the indicated times, 6pre-treatment with 30 mM PD98059. As negative controls they were treated with irrelevant antibody alone, anti-ICAM-1 MAb alone, RAM alone for 10 min. Cells were treated with 100 u / ml TNF and 100 u / ml IL-1b for 15 min as a positive control. Cells were lysed, resolved by SDS-PAGE and blotted onto nitrocellulose as described in Methods. (A) Blots were probed with anti-active Erk-1 / -2 before stripping and reprobing with an antibody directed against total Erk-1 / -2. (B) Blots were probed with anti-active JNK-1 /-2 before stripping and reprobing with an antibody directed against total JNK-1. Representative of three isolates. molecule may correspond to the GPI-linked form of which also contribute to the pathology of the disease, VCAM-1 described in the mouse [34] [35] [36] although further including the invading monocyte / macrophage and investigation is necessary (Fig. 5B) . Pre-treatment of lymphocyte populations [1] [2] [3] . We have observed ICAM-1 VSMC with the MEK inhibitor PD98059 caused abrogaexpression on the surface of VSMC isolated by explants tion of VCAM-1 induction (Fig. 5B) , suggesting that from aortic tissue and pulmonary artery tissue, and ICAM-ERK-1 / -2 signalling is involved in ICAM-1 induced 1 positive VSMC have been observed within atheros-VCAM-1 expression. In contrast, PSI, an NF-kB inhibitor clerotic lesions previously [10, 13, 15, 16] . These cells also [29] , had no effect, in agreement with our previous results produce pro-inflammatory factors, and matrix-forming [23] .
factors. It is likely that interactions between smooth muscle cells and the invading leukocytes have a role in maintaining the chronicity of the lesion. In order to mimic 4. Discussion VSMC:leukocyte interactions, we ligated ICAM-1 on the surface of VSMC. VSMC within atherosclerotic lesions have been extenIn agreement with other reports we observed an increase sively studied and their phenotype is well defined. These in phosphorylation of members of the mitogen activated cells acquire the ability to produce matrix and pro-inprotein kinase (MAPK) family after ICAM-1 cross-linkflammatory cytokines. They lose contractile function and ing. VSMC were more sensitive than HUVEC since are proliferative. There are, however, other cell types, ICAM-1 MAbs did not need to be cross-linked in order to stress responses and induction of pro-inflammatory cytokine cascades [37, 38] . Since ICAM-1 cross-linking on VSMC activates JNK-1, in vitro, we propose that this might provide an alternative pathway for the upregulation of pro-inflammatory mediators within atherosclerotic lesions and at sites of inflammation within the vasculature, where interactions between ICAM-1 expressing VSMC and leukocytes could occur. We are currently investigating whether ICAM-1 cross-linking leads to expression of proinflammatory cytokines. A characteristic feature of the atherosclerotic lesion is that VSMC migrate from the media into the intima of the effect on their proliferation (Fig. 4) . In contrast, previous work investigating the role of anti-MHC class I antibodies has shown that ligation of MHC class I with these see activation of ERK-1 / -2 cascades [23] ). We also saw antibodies can lead to increased proliferation of both activation of JNK-1 after cross-linking, which has not been vascular endothelial cells and VSMC [40] [41] [42] . This is observed in HUVEC [23] but has been previously docuaccompanied by an increase in expression of growth factor mented in rat brain MVEC [21] , where ICAM-1 crossreceptors [43] . Interestingly, Hu et al. [44] have shown that linking induced JNK-1 / -2 activity but not Erk-1 / -2 activaErk-1 / -2 is involved in LDL-induced proliferation in tion. This suggests that there is cell type / species specific VSMC isolated from atherosclerotic rabbit thoracic aortas. induction of MAPK pathways after ICAM-1 cross-linking.
Interactions of ICAM-1 with ligands other than LFA-1, JNK-1 / -2 activation has previously been associated with including fibrinogen [45] , which is expressed within the lesion [46, 47] have also been shown to activate Erks and to cells [11, 15] . It is possible that at least some of this lead to cell proliferation [48, 49] , suggesting that pathways expression may be due to interaction between infiltrating T downstream of Erk activation may be different depending cells and VSMC via ICAM-1 and LFA-1 interactions, as on the initial stimulus, in VSMC. modelled in this paper. VCAM-1 would be expected to We looked for factors that may be involved in the have pro-inflammatory effects via a number of different continued leukocyte presence within the lesion. Increased mechanisms, including retardation of very late antigen expression of VCAM-1 was observed (Fig. 5) . VCAM-1 (VLA)-4 positive infiltrating monocytes / foam cells, posexpression on the surface of VSMC within atherosclerotic sibly contributing to their activation through further integplaques has been well documented. Indeed, enhanced rin interactions. It is also possible that VCAM-1 can act as expression is observed on VSMC compared to endothelial a co-stimulatory molecule as has been shown in some 
